Recombinant human erythropoietin in the treatment of cisplatin-based-chemotherapy-induced a-nemia
- VernacularTitle:重组人红细胞生成素治疗20例含顺铂化疗诱发的贫血
- Author:
Guo-Hong SONG
;
Shu-Jun LIU
;
Li-Jun DI
;
Al ET
- Publication Type:Journal Article
- Keywords:
chemotherapy-induced anemia;
rHuEPO;
cisplatin
- From:China Oncology
2001;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To study the efficiency and the safety of recombinant human erythropoietin (rHuEPO) in the treatment of chemotherapy-induced anemia.Methods:41 tumor patients were randomized into two groups:EPO-treatment group and control group,in order to observe the changes of the haemoglobin level,transfusion requirement and quality of life for the two groups respectively.Results:①the increase of haemoglobin level and the quality of life in the EPO-treat- ment group compared with that in the control group was statistically significant.②the reduction of transfusion requirement in the EPO-treatment group compared with that in the control group was not statistically significant.③treatment of EPO has few side-effects and a good tolerance.Conclusions:rHuEPO in the treatment of chemotherapy-induced anemia is effec- tive and safe.Not only can it increase the haemoglobin level but also improve the quality of life for the patients,so it should be used widely.
